{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-002488","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.317757+00:00","generated_at":"2026-06-27T14:32:40.115249+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncotelic updates on OT-101 biomarker program pursuing accelerated approval route for solid tumors","bullets":["New corporate presentation highlights OT-101 biomarker program with pembrolizumab in multiple phase 2 trials.","Aims to leverage FDA accelerated approval pathway for TMB-H solid tumors, similar to pembrolizumab's June 2020 approval.","Phase 2 trials target solid tumors with high-TGF signature, using a companion diagnostic assay."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-002488","json":"https://secwatch.observer/filing/0001493152-22-002488.json","markdown":"https://secwatch.observer/filing/0001493152-22-002488.md","text":"https://secwatch.observer/filing/0001493152-22-002488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222002488/0001493152-22-002488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222002488/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T14:32:40.115249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}